FOS and benign prostatic hyperplasia: At the higher dose (2.0 μg/well of c-Fos/n-Myc/Max), although no significant difference in stimulation between BPL- and BPH- promoter was observed in the case of n-Myc, the BPL-promoter activation was still significantly more than the BPH-promoter in case of c-Fos (∼1.4-fold, p<0.01; Fig. 9A) and Max (∼1.6-fold, p<0.01; Fig. 9C).